☰

Zachary R. Hartman, Ph.D. - Publications

Affiliations: 
2013 School of Medicine West Virginia University, Morgantown, WV, United States 
Area:
Biochemistry, Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Butler W, Xu L, Zhou Y, Cheng Q, Hauck S, He Y, Marek R, Hartman Z, Cheng L, Yang Q, Wang ME, Chen M, Zhang H, Armstrong AJ, Huang J. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. The Journal of Pathology. PMID 36752189 DOI: 10.1002/path.6063  0.343
2020 Hartman Z, Geldenhuys WJ, Agazie YM. Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects. Acs Omega. 5: 25113-25124. PMID 33043190 DOI: 10.1021/acsomega.0c02746  0.748
2020 Hartman Z, Geldenhuys WJ, Agazie YM. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). The Journal of Biological Chemistry. PMID 32024694 DOI: 10.1074/Jbc.Ra119.011422  0.707
2020 Agazie Y, Hartman Z. Abstract P3-10-20: Targeting the tyrosine phosphatase SHP2 is efficacious against HER2-positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-10-20  0.777
2019 Agazie Y, Hartman Z. Abstract P6-20-17: Targeting SHP2 for the treatment of HER2-positive breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-20-17  0.745
2017 Osada T, Morse MA, Hobeika A, Diniz MA, Gwin WR, Hartman Z, Wei J, Guo H, Yang XY, Liu CX, Kaneko K, Broadwater G, Lyerly HK. Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. Oncoimmunology. 6: e1315495. PMID 28680745 DOI: 10.1080/2162402X.2017.1315495  0.362
2013 Hartman ZR, Schaller MD, Agazie YM. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration. Molecular Cancer Research : McR. 11: 651-64. PMID 23512980 DOI: 10.1158/1541-7786.Mcr-12-0578  0.744
2012 Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 32: 4169-80. PMID 23027125 DOI: 10.1038/Onc.2012.418  0.738
2011 Matalka F, Hartman Z, Agazie YM. Abstract 238: Inhibition of SHP2 abolishes mammary tumorigenesis in mice Cancer Research. 71: 238-238. DOI: 10.1158/1538-7445.Am2011-238  0.763
2011 Agazie Y, Matalka F, Hartman Z. P3-01-15: The Role of Src Homology Phosphotyrosyl Phosphatase-2 in Basal-Type/Triple-Negative Breast Cancer – Implications for Targeted Therapy. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-01-15  0.785
2011 Hartman Z, Agazie Y. P2-02-05: Molecular Mechanism for Src Homology Phosphotyrosyl Phosphatase 2 Regulation of Cell Motility and Migration. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-02-05  0.772
2010 Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of Cancer. 126: 2893-903. PMID 19856307 DOI: 10.1002/Ijc.24995  0.483
Show low-probability matches.